- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03637374
Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device
A Study of the Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Modified Inclusion Criteria
A patient may be entered into the study if the patient has at least one of the following:
- An aneurysm with a maximum diameter of > 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
- Aneurysm with a history of growth > 0.5 cm in 6 months
- Saccular aneurysm deemed at significant risk for rupture
- Symptomatic aneurysm greater than 4.5 cm
Other inclusion criteria:
- Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
Proximal landing zone for the thoracic bifurcation stent graft that has:
- ≥ 2.5 cm of healthy/nondiseased tissue (including previously placed graft material) (neck) distal to the left subclavian artery (LSA) diameter in the range of 26-42 mm
- ≥2.5cm of surgical graft distal to the left subclavian artery (LSA) diameter in the range of 26-42mm.
- Adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold
- Minimum branch vessel diameter greater than 5 mm
- Iliac artery distal fixation site, including both native tissue and previously placed graft, greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm
- Patency of the four major visceral vessels (SMA, celiac, right renal, left renal)
- Age: ≥ 18 years old
- Life expectancy: > 1 year
Exclusion Criteria
General exclusion
- Patient is a good candidate for and elects open surgical repair
- Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis
- Is eligible for enrollment in a manufacturer-sponsored investigational device exemption (IDE) at the investigational site
- Unwilling to comply with the follow-up schedule
- Inability or refusal to give informed consent by patient or legal representative
- Patient is pregnant or breastfeeding
- Patient has a contained rupture
- Patient has a ruptured aneurysm
- Patient has a dissection in the treated portion of the aorta
- Obstructive stenting of any or all of the visceral vessels
Medical exclusion criteria
- Known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel: Titanium), polyester, platinum-iridium, polytetrafluoroethylene (PTFE), platinum, gold, polyethylene, or stainless steel.
- Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
- Uncorrectable coagulopathy
- Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
- Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair
- Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
- Systemic or local infection that may increase the risk of endovascular graft infection
- Baseline creatinine greater than 2.0 mg/dL
- History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
Anatomical exclusion criteria
- Thrombus or excessive calcification within the neck of the aneurysm
- Branch stenosis ≥ 70%
- Anatomy that would not allow maintenance of at least one patent hypogastric artery
- Anatomy that would not allow primary or assisted patency of the left subclavian artery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Primary Study Arm
The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold.
The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
|
Endovascular stent graft system
Endovascular stent graft system
Endovascular stent graft system
|
Other: Expanded Selection Arm
The Expanded Selection Arm will be treated the same as those in the Primary Study Arm.
Your doctor will determine what arm you are in.
TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold.
The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
|
Endovascular stent graft system
Endovascular stent graft system
Endovascular stent graft system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom From Major Adverse Events (MAEs) at 30 Days
Time Frame: 30 days
|
Major adverse events include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, and stroke.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Success at 1 Year
Time Frame: 1 year
|
Treatment success is defined as a composite of technical success and freedom from the following: Aneurysm enlargement, Aneurysm rupture, Aneurysm-related mortality, Conversion to open repair, Secondary intervention for migration, Type I and III endoleaks, device integrity failure, and patency-related events. |
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James H Black, MD, Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00075706
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracoabdominal Aortic Aneurysm
-
The Christ HospitalMedtronicRecruiting
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingThoracoabdominal Aortic AneurysmsChina
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Assiut UniversityNot yet recruitingThoracoabdominal Aortic Aneurysm
-
JOTEC GmbHRecruitingThoracoabdominal Aortic AneurysmNew Zealand, Thailand, Australia
-
W.L.Gore & AssociatesCompletedThoracoabdominal Aortic AneurysmUnited States
-
JOTEC GmbHRecruiting
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
Uppsala UniversityNot yet recruitingThoracoabdominal Aortic Aneurysm
Clinical Trials on Visceral Manifold and Thoracic Bifurcation
-
Sanford HealthActive, not recruitingThoracoabdominal AneurysmsUnited States
-
University of SorocabaCompleted
-
Ulrich Ronellenfitsch, MDRecruiting
-
Instituto Docusse de Osteopatia e Terapia ManualCompletedHealthy VolunteersBrazil
-
Mansoura UniversityCompletedUrologic Diseases | Obesity, Abdominal | Overactive Bladder Syndrome
-
University of SorocabaCompletedStroke Rehabilitation
-
University of Nove de JulhoDaniela Aparecida Biasotto-Gonzalez; Marco Antônio Fumagalli; Cid André Fidelis... and other collaboratorsCompletedFunctional Dyspepsia | Neck Pain
-
Youngstown State UniversityFranklin Pierce UniversityCompletedNeck PainUnited States
-
Ziv HospitalUnknownVisceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary AtherosclerosisAtherosclerosis | Fatty Liver | Visceral Fat | Coronary Computed Tomography AngiographyIsrael
-
Ziv HospitalUnknownAtherosclerosis | Visceral Fat | Epicardial FatIsrael